Treatment of intercarpal joint lameness using ArthramidVet 2.5% PAAG
Elmo was a 7-year-old Warmblood-Thoroughbred cross gelding competing at the height of 1.4m in Showjumping. Over 12 weeks, his performance reduced to a point where he started to resent training…
Treatment of joint lameness and osteoarthritis (OA) in horses
Osteoarthritis (OA) is considered one of the most important musculoskeletal disorders in both humans and horses. Clinically, it is associated with lameness and dysfunction of the affected joint and approximately…
Treatment of intercarpal (knee) joint lameness in TB racehorses
Use Of a 2.5% Cross-Linked Polyacrylamide Hydrogel In The Management Of Joint Lameness In a Population Of Flat Racing Thoroughbreds: A Pilot Sudy Published in JEVS; https://www.sciencedirect.com/science/article/pii/S0737080618307615 Abstract Osteoarthritis is one…
Clinical Safety of Arthramid Vet 2.5% PAAG Hydrogel
Both in vitro and in vivo studies have taken place, designed to generate data on the safety of Arthramid Vet and to support regulatory submissions for market authorisation. Most current…
Arthramid Vet 2.5% PAAG Hydrogel- Efficacy Study Abstract
Intra-articular administration of a 2.5% polyacrylamide hydrogel (PAAG- Arthramid Vet) is shown to reduce or abolish lameness in distal interphalangeal (coffin) and metacarpo/ metatarso- phalangeal (fetlock) joints in horses undertaking…
Arthramid Vet 2.5% PAAG – Mechanism Of Action
Osteoarthritis (OA) describes inflammation of a joint and occurs after single or repetitive episodes of trauma. The term incorporates synovitis, capsulitis, sprain, intra-articular fractures, meniscal tears, and OA. These pathological…
